CN104152515A - Medium used for preparation of recombinant human granulocyte colony stimulating factor and fermentation method - Google Patents
Medium used for preparation of recombinant human granulocyte colony stimulating factor and fermentation method Download PDFInfo
- Publication number
- CN104152515A CN104152515A CN201410401268.6A CN201410401268A CN104152515A CN 104152515 A CN104152515 A CN 104152515A CN 201410401268 A CN201410401268 A CN 201410401268A CN 104152515 A CN104152515 A CN 104152515A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- medium
- csf
- lactose
- tryptones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a medium used for preparation of a recombinant human granulocyte colony stimulating factor and a fermentation method, belonging to the technical field of fermentation engineering. The method comprises the following steps: culturing a recombinant bacterium seed liquid; inoculating the seed liquid into a fermentation medium; replenishing a supplemented medium during fermentation; and acquiring fermentation broth after completion of fermentation. The fermentation medium and the supplemented medium both contain inducer lactose; the fermentation medium comprises (g/L) 15 to 20 of tryptone, 10 to 20 of yeast extract, 10 to 20 of sodium chloride, 1 to 5 of lactose and water; the supplemented medium comprises (g/L) 50 to 100 of tryptone, 25 to 50 of yeast extract, 300 to 500 of glycerin, 2 to 6 of lactose and water. According to the invention, technology is simplified, cost is low, safety and non-toxicity are realized, thallus yield and the expression level of protein are improved, and realization of industrial production is facilitated.
Description
Technical field
The invention belongs to microbial fermentation engineering technical field, be specifically related to a kind of substratum and fermentation process of preparing recombinant methionyl human G-CSF.
Background technology
Filgrastim (human granulocyte colony-stimulating factors, hG-CSF) be one species specific act on grain be progenitor cell, promote its to ripe neutrophil leucocyte breed, break up and maintain its function, the necessary glycoprotein hemopoieticgrowth factor of surviving.1986, from people's squamous cell cancerous cell line CHU-II, separate hG-CSF gene by Nagata etc., determine first its nucleotide sequence and at COS cells (Nagata S et al, Nature, 1986,319:415-418).The mankind have two kinds of different G-CSF cDNA, coding is containing 207 and 204 amino acid whose precursor proteins respectively, all there are 30 amino acid whose signal peptides, maturation protein molecule is 177 and 174 amino acid, the former is except having inserted 3 amino acid at 35 places of ripe molecule N end, and remaining sequence is identical with 174 amino acid moleculars.Human G-CSF molecular weight is 19.6kD, and PI is 6.1, O-glycosylation, relatively stable to soda acid (pH2～10), heat and denaturing agent etc.HG-CSF has 5 cysteine residues, and wherein 4 cysteine residues, at Cys36 and Cys42, form two pairs of disulfide linkage between Cys74 and Cys64; Cys17 is unpaired halfcystine, and the formation of disulfide linkage is extremely important for maintaining G-CSF biological function.
G-CSF is significant in clinical application, can promote the recovery of neutrophilic leukocyte when bone marrow transplantation; Improve the neutrocyte deficiency disease that aplastic anemia is followed; The serious neutrophil leucocyte causing while obviously improving cancer chemotherapy lacks, and strengthens the dynamics of oncotherapy, strengthens result for the treatment of; Be widely used in other diseases that reduce with neutrophil leucocyte and anti-infective etc. treatment.G-CSF natural product source is very limited, can not meet needs clinically far away, and the biologic activity of engineered restructuring G-CSF is to natural similar, and the G-CSF that can be mass-produced.
1985, Welte K successful purifying refine out hG-CSF from the culture supernatant of 5637 cell line, Welte K and Souza L M further determine again the N section sequence of amino acid of this hG-CSF afterwards, the hG-CSF gene cloning of 5637 cell strains will be derived from, adopt genetic engineering technique that this gene is inserted to intestinal bacteria and successfully make hG-CSF, thereby develop recombinant methionyl human G-CSF rhG-CSF, commodity are called Filgratin (G-CSF).This medicine obtained U.S. FDA approval listing in 1991.1993, first the people such as Qu Chengkui cloned human G-CSF cDNA at home, and obtained and express in intestinal bacteria.After this, many research staff are also devoted to the research of this respect, because G-CSF has the shortcoming that expression amount is low, biologic activity is not so good as natural product in prokaryotic organism, continue to optimize zymotechnique, improve the quality of products, and reduce production costs and seem very important.
At present the research of rhG-CSF fermentation manufacturing technique is mainly concentrated on the aspects such as engineering strain, high density fermentation cultivation and renaturing inclusion bodies, purifying.Abduction delivering is the most frequently used and effective strategy of clonal expression recombinant protein in intestinal bacteria at present.The mode of induction mainly contains three kinds: IPTG (sec.-propyl-β-D-sulfydryl galactoside), thermal induction and lactose-induced.The main employing IPTG induction at present of rhG-CSF zymotechnique or thermal induction (as, 42 DEG C).IPTG is one Lac operon inductor very efficiently, and IPTG inductive condition is simple, effect lasting stability; but IPTG has potential toxicity; pharmacopoeia of each country is not all advocated use, and expensive, thereby is not suitable for carrying out the large-scale production of gene engineering product in fermentor tank.In addition, thermal induction easily causes renaturing inclusion bodies difficulty, and renaturation yield reduces.Lactose is a kind of disaccharides, there is no toxicity, the natural effect with induction lactose operon, and cheap and easy to get, thereby may become the inductor that substitutes IPTG, for the various scale operation that utilizes prokaryotic expression system to carry out recombinant protein, be of great practical significance and using value.But because lactose is in making inductor, also can be utilized as carbon metabolism by cell, its concentration is dynamic change, and transhipment and transform and relate to the participation of multiple enzymes, abduction mechanism is more more complicated than IPTG, inductive condition is difficult for grasping, and need to carry out more meticulous research and optimize and could induce restructuring thalline fermentation expression hG-CSF by stability and high efficiency thalli growth and inductive condition.
Summary of the invention
One of object of the present invention is to provide a kind of high efficient expression substratum of preparing recombinant methionyl human G-CSF, it comprises lactose as inductor and carbon source, research by the proportioning of carbon source, nitrogenous source, inductor and other nutritive ingredient contamination, each substratum in substratum breaks through, and has solved in prior art lactose as the complex process of carbon source and inductor, the difficult problem that expression of recombinant proteins amount is low; Another object of the present invention is to provide a kind of and adopts above-mentioned high efficient expression substratum to prepare the fermentation process of recombinant methionyl human G-CSF, described fermentation process is included in inductor in substratum, IPTG induction and thermal induction general procedure are saved, simplify technique, in addition, lactose nontoxicity, and cheap, be suitable for the recombinating large-scale commercial production of medical protein, has extremely important value.
Technical scheme of the present invention is: a kind of substratum of preparing recombinant methionyl human G-CSF, comprise seed culture medium, fermention medium and supplemented medium, the composition of described fermention medium and content thereof are: Tryptones 15～20g/L, yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 50～100g/L, yeast extract 25～50g/L, and glycerine 300～500g/L, lactose 2～6g/L, surplus is water; Described supplemented medium by volume calculates as 20%～30% of described fermention medium volume.
Further, the composition of described fermention medium and content thereof are: Tryptones 18～20g/L, and yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 70～100g/L, yeast extract 40～50g/L, and glycerine 360～500g/L, lactose 2～6g/L, surplus is water.
Preferably, the composition of described seed culture medium and content thereof are Tryptones 15～25g/L, preferably 20～25g/L, and yeast powder 7～14g/L, preferably 10～14g/L, sodium-chlor 6～15g/L, preferably 10～15g/L, surplus is water, pH value is adjusted to 7.0～7.2; Described seed culture medium by volume calculates as 1%～3% of described fermention medium volume.
The present invention also provides the fermentation process that utilizes above-mentioned substratum to prepare recombinant methionyl human G-CSF, and its concrete steps are as follows:
1.. the Host Strains of the gene constructed transfer vector plasmid obtaining of trans-utilization pET-9a carrier and human G-CSF is inoculated in to seed culture medium and is cultured to OD
600be 0.8～1.2, obtain fermentation seed liquid, described human G-CSF gene order is as shown in SEQ ID No.1;
2.. fermentation seed liquid is inoculated in the fermention medium of sterilizing in 1%～3% ratio of fermention medium volume, cultivates 3～6 hours;
3.. continue fermentation in 20%～30% ratio of fermention medium volume to the supplemented medium of adding sterilizing in fermentation system, after 18～22 hours, finish fermentation and obtain recombinant bacterium fermented liquid, the composition of described fermention medium and content thereof are: Tryptones 15～20g/L, yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 50～100g/L, yeast extract 25～50g/L, and glycerine 300～500g/L, lactose 2～6g/L, surplus is water.
Further, the composition of described fermention medium and content thereof are: Tryptones 18～20g/L, and yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 70～100g/L, yeast extract 40～50g/L, and glycerine 360～500g/L, lactose 2～6g/L, surplus is water.
Preferably, the described Host Strains that has transformed transfer vector plasmid is inoculated in seed culture medium and cultivates that to obtain fermentation seed liquid be transformed the Host Strains of transfer vector plasmid and be inoculated into the culturing bottle that contains seed culture medium from glycerine pipe bacterial classification picking, inoculum size is 0.1%, under 35～39 DEG C, the condition of 160～180rpm, cultivate 8～10 hours, be fermentation seed liquid.
Preferably, the composition of described seed culture medium and content thereof are Tryptones 15～25g/L, preferably 20～25g/L, and yeast powder 7～14g/L, preferably 10～14g/L, sodium-chlor 6～15g/L, preferably 10～15g/L, surplus is water, pH value is adjusted to 7.0～7.2.
Temperature is the important factor of engineering bacterium fermentation growth, and it can affect absorbing of the activity of growth velocity, biochemical reaction rate, enzyme system of thalline and matrix etc.PH has impact for the normal growth of cell and the high efficient expression of foreign protein.There are HCl, H for the conventional bronsted lowry acids and bases bronsted lowry of controlling pH value
3pO
4, H
2sO
4, NaOH, KOH, NH
3h
2o etc.Shaking speed is also the important factor of control engineering bacterium fermentation growth.In the process of fermentation growth, need to, according to the metabolism and growth situation of engineering bacteria, shaking speed be adjusted, so that expression of recombinant proteins amount reaches the best.
Preferably, during the fermentation, the culture temperature of described fermentation is 35～39 DEG C, by reactor auto-feeding bronsted lowry acids and bases bronsted lowry solution controlled fermentation system pH 6.0～7.5; Ferment 0 to 8 hour, fermentor tank rotating speed is 300～400rpm, and after 8 hours, adjustment of rotational speed is 200～400rpm; After fermentation seed liquid is inoculated into fermention medium, regulate rotating speed, air flow quantity and tank pressure to proofread and correct dissolved oxygen initial value as 100%, in fermenting process, no longer control oxygen dissolving value.
Further, the bronsted lowry acids and bases bronsted lowry solution that described controlled fermentation system pH uses is hydrochloric acid and sodium hydroxide solution, preferably 25% hydrochloric acid and 16% sodium hydroxide solution.
The training method of genetic engineering bacterium has: batch culture, fed batch cultivation, cultured continuously, dialysis culture and immobilization cultivation etc.Batch culture and fed batch cultivation are one of the most frequently used cultural methods.Batch culture is to join in fermentor tank disposable all nutritive substances, and fermentation ends after product obtains once.Fed batch cultivation is that seed is accessed in fermentor tank and cultivated, and through after a period of time, the partial or continuous fresh culture of adding, makes the cultural method of thalline further growth.Fed batch cultivation method is again feeding culture, it is taking batch culture as basis, add carbon source, nitrogenous source, inorganic salt etc., to solve the inhibition of carbon source, nitrogenous source, the restraining effect of eliminating high concentration substrate cell growth, also can make up the defect that lower concentration substrate is unfavorable for Growth of Cells, thereby effectively control the process of growth of thalline, the logarithmic phase that has extended thalline, has improved cell density.Conventional feeding strategy has: the methods such as constant speed, progressively increase and index are reinforced.
Preferably, the mode that the supplemented medium of described sterilizing adds with stream is added in described fermentation system, and the feed supplement time is 10 hours, and feed rate is set as feed supplement volume divided by feed supplement time institute's value.In a preferred embodiment of the invention, feed supplement cumulative volume is 2L, and feed rate is 2L/10h=200mL/h.In another preferred embodiment of the present invention, feed supplement cumulative volume is 5L, and feed rate is 5L/10h=500mL/h.
Preferably, described Host Strains is intestinal bacteria (Escherichia coli) BL21 (DE3).
As well known to the skilled person, above related seed culture medium, fermention medium and supplemented medium are before use all through 115～121 DEG C of sterilizing 15～20min.
The invention has the advantages that:
(1) successfully use lactose in high density fermentation, to substitute the expression system stability and high efficiency expression recombinant methionyl human G-CSF that IPTG induction builds based on lactose operon mechanism;
(2) in the methods of the invention, be included in substratum as the lactose of inductor, in whole fermenting process, cultivate and induce, unlike thermal induction or IPTG derived need additional step, simplified technique, and thalli growth is fast, favorable repeatability, significantly shortens fermentation period.In addition, exist without IPTG, aftertreatment is also simple.
(3) compared with IPTG, lactose is much cheap, and lactose do not have toxicity, its a small amount of residual minimum on human body impact in product.The inventive method is conducive to set up the preparation technology of rhG-CSF low cost, safety non-toxic.
(4) the present invention conducts in-depth research and optimizes rhG-CSF engineering bacterium fermentation technique, pass through technical solutions according to the invention, e. coli bl21 (DE3) thalline yield is high, thalline weight in wet base reaches 20～40g/L, target protein expression amount is high, the level that hG-CSF accounts for bacterial protein can reach 40～70%, is on close level with IPTG induction.
Brief description of the drawings
Fig. 1 is the plasmid map of the pET-9a-G-CSF for preparing of embodiment mono-;
Fig. 2 is the growth curve chart of engineering bacteria in 10L fermentor tank;
Fig. 3 is the growth curve chart of engineering bacteria in 50L fermentor tank.
Embodiment
The invention provides and a kind ofly prepare the substratum of recombinant methionyl human G-CSF and utilize described substratum to prepare the fermentation process of recombinant methionyl human G-CSF, enumerate embodiment below and be further described.
Embodiment mono-
The structure of 1.pET-9a-G-CSF prokaryotic expression bacterial strain
Human G-CSF gene order is as shown in SEQ ID No.1.Human G-CSF gene according to conventional molecular cloning method composition sequence as shown in SEQ ID No.1 is also introduced terminator TAA and goal gene two ends NdeI and BamHI restriction enzyme site; With NdeI and BamHI to prokaryotic expression plasmid vector pET-9a and human G-CSF gene fragment double digestion respectively, pET-9a after double digestion is connected with human G-CSF gene fragment, obtains being transformed in E.coli DH5 α bacterial strain after pET-9a-G-CSF recombinant plasmid (Fig. 1).More than work and complete by Nanjing Jin Sirui.
The E.coli DH5 α bacterial strain that contains pET-9a-G-CSF recombinant plasmid is inoculated into 1% inoculum size in the LB substratum that contains 50 μ g/mL kantlex, shaking table at 37 DEG C (180rpm) overnight incubation, use plasmid to extract plasmid purification without extraction reagent kit in intracellular toxin (purchased from Biomega company), plasmid after purifying imports E.coli BL21 (DE3) (purchased from Invitrogen company) according to the method for transformation in " molecular cloning ", re-uses the LB agar plate screening positive clone that contains 50 μ g/mL kantlex.Select 10 positive colony list bacterium colonies, be inoculated in respectively in SuperBroth substratum (containing 50 μ g/mL kantlex, 4.1%SuperBroth, 1g/L lactose) after mark, shaking table at 37 DEG C (180rpm) is cultivated 20～24 hours.Get 500 μ l bacterium liquid and collect bacterium mud in 3500rpm is centrifugal after abandoning supernatant, with the resuspended bacterium mud of 1mL PBS, get the bacteria suspension 15 μ l after resuspended, add 15 μ l2 × sample-loading buffers (Loading Buffer), put boiling water bath 5min, in the centrifugal 5min of 10000rpm, get supernatant 15 μ l and carry out the whole bacterium electrophoresis of SDS-PAGE, deposition condition is: 4.5% concentrated glue 100v electrophoresis 10min, 15% separation gel 120v electrophoresis is bottom to tetrabromophenol sulfonphthalein to gel, stops electrophoresis.After end, use coomassie brilliant blue staining 30min, then the 3h that decolours, upper BIO-RAD gel imaging system detects G-CSF expression amount.Select expression amount to be 40% bacterial classification to the maximum and carry out PCR and order-checking qualification, and by its called after E.coliBL21 (DE3)-pET-9a-G-CSF.
2. conservation
The mono-colony inoculation of E.coliBL21 after Screening and Identification (DE3)-pET-9a-G-CSF (is contained to 50 μ g/mL kantlex in SuperBroth substratum, 4.1%SuperBroth), shaking table at 37 DEG C (180rpm) is cultivated 6～8 hours, treats OD
600reach 1, stop cultivating, add sterile glycerol, make glycerol concentration reach 15%, be sub-packed in sterilizing cryopreservation tube ,-80 DEG C of preservations are for subsequent use.
Embodiment bis-(taking 10L fermentor tank as example)
1. the cultivation of seed: seed culture medium 210mL is housed in 500mL triangular flask, 121 DEG C of moist heat sterilization 15min, cool to room temperature.Get E.coliBL21 (DE3)-pET-9a-G-CSF glycerine pipe bacterial classification prepared by embodiment mono-, be inoculated in seed culture medium, inoculum size is 0.1%, and shaking culture 8 hours in the shaking table that is 160rpm at 35 DEG C of temperature, rotating speed is measured OD
600be 0.8, obtain ferment-seeded nutrient solution.Wherein the composition of seed culture medium and content thereof are: Tryptones 15g/L, and yeast powder 7g/L, sodium-chlor 6g/L, formulated with deionized water, after sterilizing, be 7.0 by its pH regulator.On inspection, the bacterial classification of this cultivation has no microbiological contamination, thalli morphology is better.
Inoculation before prepare: first fermentor tank is cleaned up, fermention medium is dissolved in purified water, stir, pour in fermentor tank, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, be cooled to 35 DEG C for subsequent use.Wherein consisting of of fermention medium: Tryptones 15g/L, yeast extract 14g/L, NaCl15g/L, lactose 3g/L.
Supplemented medium is dissolved in purified water, stirs, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, cooling rear for subsequent use.Wherein consisting of of supplemented medium: Tryptones 50g/L, yeast extract 25g/L, glycerine 300g/L, lactose 4g/L.
3. inoculation: under flame protection, ferment-seeded nutrient solution 70mL being up to the standards by 1% inoculum size of fermention medium volume is inoculated in 10L fermentor tank, liquid amount 7L, 35 DEG C of culture temperature, mixing speed is 300rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 3h starts the supplemented medium that stream adds in step 2 preparation, feed rate 140mL/h, supplemented medium volume 1.4L;
4.2 ferment to 8h, and rotating speed is adjusted into 200rpm by 300rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 1.4L;
PH=6.1 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 18h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 16.1, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 169g, target protein G-CSF accounts for bacterial protein 40.2%, and wet bacterium mud obtains inclusion body 25.6g after cytoclasis.
Embodiment tri-(taking 10L fermentor tank as example)
1. the cultivation of seed: seed culture medium 210mL is housed in 500mL triangular flask, 121 DEG C of moist heat sterilization 15min, cool to room temperature.Get E.coliBL21 (DE3)-pET-9a-G-CSF glycerine pipe bacterial classification prepared by embodiment mono-, be inoculated in seed culture medium, inoculum size is 0.1%, and shaking culture 9 hours in the shaking table that is 180rpm at 37 DEG C of temperature, rotating speed is measured OD
600be 1.2, obtain ferment-seeded nutrient solution.Wherein the composition of seed culture medium and content thereof are: Tryptones 20g/L, and yeast powder 10g/L, sodium-chlor 10g/L, formulated with deionized water, after sterilizing, be 7.1 by its pH regulator.On inspection, the bacterial classification of this cultivation has no microbiological contamination, thalli morphology is better.
Inoculation before prepare: first fermentor tank is cleaned up, fermention medium is dissolved in purified water, stir, pour in fermentor tank, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, be cooled to 37 DEG C for subsequent use.Wherein consisting of of fermention medium: Tryptones 20g/L, yeast extract 10g/L, NaCl10g/L, lactose 1g/L.
Supplemented medium is dissolved in purified water, stirs, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, cooling rear for subsequent use.Wherein consisting of of supplemented medium: Tryptones 100g/L, yeast extract 50g/L, glycerine 360g/L, lactose 2g/L.
3. inoculation: under flame protection, ferment-seeded nutrient solution 210mL being up to the standards by 3% inoculum size of fermention medium volume is inoculated in 10L fermentor tank, liquid amount 7L, 37 DEG C of culture temperature, mixing speed is 375rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 5h starts the supplemented medium that stream adds in step 2 preparation, feed rate 200mL/h, supplemented medium volume 2L;
4.2 ferment to 8h, and rotating speed is adjusted into 250rpm by 375rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 2L;
PH=7.0 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 20h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 22.4, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 270.2g, target protein G-CSF accounts for bacterial protein 71%, and wet bacterium mud obtains inclusion body 45.6g after cytoclasis.
Embodiment tetra-(taking 10L fermentor tank as example)
1. the cultivation of seed: seed culture medium 210mL is housed in 500mL triangular flask, 121 DEG C of moist heat sterilization 15min, cool to room temperature.Get E.coliBL21 (DE3)-pET-9a-G-CSF glycerine pipe bacterial classification prepared by embodiment mono-, be inoculated in seed culture medium, inoculum size is 0.1%, and shaking culture 10 hours in the shaking table that is 170rpm at 39 DEG C of temperature, rotating speed is measured OD
600be 1.0, obtain ferment-seeded nutrient solution.Wherein the composition of seed culture medium and content thereof are: Tryptones 25g/L, and yeast powder 14g/L, sodium-chlor 15g/L, formulated with deionized water, after sterilizing, be 7.2 by its pH regulator.On inspection, the bacterial classification of this cultivation has no microbiological contamination, thalli morphology is better.
Inoculation before prepare: first fermentor tank is cleaned up, fermention medium is dissolved in purified water, stir, pour in fermentor tank, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, be cooled to 39 DEG C for subsequent use.Wherein consisting of of fermention medium: Tryptones 18g/L, yeast extract 20g/L, NaCl20g/L, lactose 5g/L.
Supplemented medium is dissolved in purified water, stirs, the 121 DEG C of damp and hot off-line sterilizing of steam 20min, cooling rear for subsequent use.Wherein consisting of of supplemented medium: Tryptones 70g/L, yeast extract 40g/L, glycerine 500g/L, lactose 6g/L.
3. inoculation: under flame protection, ferment-seeded nutrient solution 110mL being up to the standards by 1.6% inoculum size of fermention medium volume is inoculated in 10L fermentor tank, liquid amount 7L, 39 DEG C of culture temperature, mixing speed is 400rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 6h starts the supplemented medium that stream adds in step 2 preparation, feed rate 210mL/h, supplemented medium volume 2.1L;
In 4.2 fermenting processs, mixing speed remains 400rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 2.1L;
PH=7.4 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 22h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 18.6, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 227.5g, target protein G-CSF accounts for bacterial protein 64%, and wet bacterium mud obtains inclusion body 36.4g after cytoclasis.Engineering bacteria growth curve is shown in Fig. 2.
Embodiment five (taking 50L fermentor tank as example)
1. the cultivation of seed: the cultivation of the present embodiment seed is identical with embodiment bis-.
2. before inoculation, prepare: before the present embodiment inoculation, prepare identical with embodiment bis-.
3. inoculation: under flame protection, ferment-seeded nutrient solution 250mL being up to the standards by 1% inoculum size of fermention medium volume is inoculated in 50L fermentor tank, liquid amount 25L, 35 DEG C of culture temperature, mixing speed is 300rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 3h starts the supplemented medium that stream adds in step 2 preparation, feed rate 625mL/h, supplemented medium volume 6.25L;
4.2 ferment to 8h, and rotating speed is adjusted into 200rpm by 300rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 6.25L;
PH=6.1 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 18h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 22.3, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 937.6g, target protein G-CSF accounts for bacterial protein 42%, and wet bacterium mud obtains inclusion body 93.8g after cytoclasis.
Embodiment six (taking 50L fermentor tank as example)
1. the cultivation of seed: the cultivation of the present embodiment seed is identical with embodiment tri-.
2. before inoculation, prepare: before the present embodiment inoculation, prepare identical with embodiment tri-.
3. inoculation: under flame protection, ferment-seeded nutrient solution 400mL being up to the standards by 1.6% inoculum size of fermention medium volume is inoculated in 50L fermentor tank, liquid amount 25L, 37 DEG C of culture temperature, mixing speed is 375rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 5h starts the supplemented medium that stream adds in step 2 preparation, feed rate 500mL/h, supplemented medium volume 5L;
4.2 ferment to 8h, and rotating speed is adjusted into 250rpm by 375rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 5L;
PH=7.0 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 20h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 31.5, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 1203g, target protein G-CSF accounts for bacterial protein 71.3%, and wet bacterium mud obtains inclusion body 152g after cytoclasis.Engineering bacteria growth curve is shown in Fig. 3.
Embodiment seven (taking 50L fermentor tank as example)
1. the cultivation of seed: the cultivation of the present embodiment seed is identical with embodiment tetra-.
2. before inoculation, prepare: before the present embodiment inoculation, prepare identical with embodiment tetra-.
3. inoculation: under flame protection, ferment-seeded nutrient solution 750mL being up to the standards by 3% inoculum size of fermention medium volume is inoculated in 50L fermentor tank, liquid amount 25L, 39 DEG C of culture temperature, mixing speed is 400rpm, starts fermentation culture.It is 100% that dissolved oxygen initial value is proofreaied and correct by adjusting rotary speed, air flow quantity and tank pressure after fermentation seed liquid is inoculated into fermention medium, no longer controls oxygen dissolving value in fermenting process.
4. fermentation: adopt following intermediate control methods in fermenting process:
4.1 ferment to 6h starts the supplemented medium that stream adds in step 2 preparation, feed rate 750mL/h, supplemented medium volume 7.5L;
In 4.2 fermenting processs, mixing speed remains 400rpm;
In 4.3 the present embodiment fermenting processs, total feed supplement amount is 7.5L;
PH=7.4 ± 0.1 in 4.4 the present embodiment fermenting processs, by reactor auto-feeding 16.0%NaOH solution, 25%HCl solution regulates;
4.5 ferment finishes after 22h, obtains zymocyte liquid.
5. experimental result: after testing, zymocyte liquid OD
600reach 27, adopt tubular-bowl centrifuge to collect thalline, obtain wet bacterium mud 1137.2g, target protein G-CSF accounts for bacterial protein 65.5%, and wet bacterium mud obtains inclusion body 130.2g after cytoclasis.
The present invention produces for recombinant methionyl human G-CSF, has broad application prospects.By the lactose-induced fermentation manufacturing technique of research and development recombinant methionyl human G-CSF engineering bacteria, make operation more simple, and reduced production cost, realized safety non-toxic, improve thalline yield and target protein expression amount, be conducive to realize suitability for industrialized production.
Finally it should be noted that, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although by with reference to the preferred embodiments of the present invention, invention has been described, but those of ordinary skill in the art is to be understood that, can modify or be equal to replacement technical scheme of the present invention, and not departing from aim and the scope of the technical program, it all should be encompassed in the middle of claim scope of the present invention.
Claims (10)
1. prepare the substratum of recombinant methionyl human G-CSF for one kind, comprise seed culture medium, fermention medium and supplemented medium, the composition and the content thereof that it is characterized in that described fermention medium are: Tryptones 15～20g/L, yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 50～100g/L, yeast extract 25～50g/L, and glycerine 300～500g/L, lactose 2～6g/L, surplus is water; Described supplemented medium by volume calculates as 20%～30% of described fermention medium volume.
2. the substratum of preparing recombinant methionyl human G-CSF according to claim 1, the composition and the content thereof that it is characterized in that described seed culture medium are Tryptones 15～25g/L, preferably 20～25g/L, yeast powder 7～14g/L, preferably 10～14g/L, sodium-chlor 6～15g/L, preferably 10～15g/L, surplus is water, and pH value is adjusted to 7.0～7.2; Described seed culture medium by volume calculates as 1%～3% of described fermention medium volume.
3. utilize substratum described in claim 1 or 2 to prepare a fermentation process for recombinant methionyl human G-CSF, its concrete steps are as follows:
1.. the Host Strains of the gene constructed transfer vector plasmid obtaining of trans-utilization pET-9a carrier and human G-CSF is inoculated in to seed culture medium and is cultured to OD
600be 0.8～1.2, obtain fermentation seed liquid, described human G-CSF gene order is as shown in SEQ ID No.1;
2.. fermentation seed liquid is inoculated in the fermention medium of sterilizing in 1%～3% ratio of fermention medium volume, cultivates 3～6 hours;
3.. continue fermentation in 20%～30% ratio of fermention medium volume to the supplemented medium of adding sterilizing in fermentation system, after 18～22 hours, finish fermentation and obtains recombinant bacterium fermented liquid,
It is characterized in that, the composition of described fermention medium and content thereof are: Tryptones 15～20g/L, and yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 50～100g/L, yeast extract 25～50g/L, and glycerine 300～500g/L, lactose 2～6g/L, surplus is water.
4. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 3, the composition and the content thereof that it is characterized in that described fermention medium are: Tryptones 18～20g/L, yeast extract 10～20g/L, sodium-chlor 10～20g/L, lactose 1～5g/L, surplus is water; The composition of described supplemented medium and content thereof are: Tryptones 70～100g/L, yeast extract 40～50g/L, and glycerine 360～500g/L, lactose 2～6g/L, surplus is water.
5. according to the fermentation process of preparing recombinant methionyl human G-CSF described in claim 3 or 4, the Host Strains that has transformed transfer vector plasmid described in it is characterized in that is inoculated in seed culture medium and cultivates that to obtain fermentation seed liquid be transformed the Host Strains of transfer vector plasmid and be inoculated into the culturing bottle that contains seed culture medium from glycerine pipe bacterial classification picking, inoculum size is 0.1%, under 35～39 DEG C, the condition of 160～180rpm, cultivate 8～10 hours, be fermentation seed liquid.
6. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 5, the composition and the content thereof that it is characterized in that described seed culture medium are Tryptones 15～25g/L, preferably 20～25g/L, yeast powder 7～14g/L, preferably 10～14g/L, sodium-chlor 6～15g/L, preferably 10～15g/L, surplus is water, and pH value is adjusted to 7.0～7.2.
7. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 3, is characterized in that during the fermentation, and the culture temperature of described fermentation is 35～39 DEG C, by acid adding and alkaline solution controlled fermentation system pH 6.0～7.5; Ferment 0 to 8 hour, fermentor tank rotating speed is 300～400rpm, and after 8 hours, adjustment of rotational speed is 200～400rpm.
8. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 7, is characterized in that the bronsted lowry acids and bases bronsted lowry solution that described controlled fermentation system pH uses is hydrochloric acid and sodium hydroxide solution.
9. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 3, it is characterized in that the mode that the supplemented medium of described sterilizing adds with stream adds in described fermentation system, the feed supplement time is 10 hours, and feed rate is set as feed supplement volume divided by feed supplement time institute's value.
10. the fermentation process of preparing recombinant methionyl human G-CSF according to claim 3, is characterized in that described Host Strains is intestinal bacteria (Escherichia coli) BL21 (DE3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401268.6A CN104152515B (en) | 2014-08-14 | 2014-08-14 | Culture medium for preparing recombinant human granulocyte colony stimulating factor and fermentation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410401268.6A CN104152515B (en) | 2014-08-14 | 2014-08-14 | Culture medium for preparing recombinant human granulocyte colony stimulating factor and fermentation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104152515A true CN104152515A (en) | 2014-11-19 |
| CN104152515B CN104152515B (en) | 2019-12-31 |
Family
ID=51878141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410401268.6A Active CN104152515B (en) | 2014-08-14 | 2014-08-14 | Culture medium for preparing recombinant human granulocyte colony stimulating factor and fermentation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104152515B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105002103A (en) * | 2015-06-06 | 2015-10-28 | 山东新时代药业有限公司 | Fermentation method for recombinant G-CSF(15-75) polypeptide pichia pastoris |
| CN106995793A (en) * | 2017-01-18 | 2017-08-01 | 天津市中升挑战生物科技有限公司 | A kind of fermentation process in high density for recombinating bG-CSF engineering bacteria |
| CN110066331A (en) * | 2018-01-23 | 2019-07-30 | 江苏恒瑞医药股份有限公司 | A kind of preparation method of recombinant human granulocyte colony stimulating factor |
| CN114350588A (en) * | 2021-12-31 | 2022-04-15 | 山东新时代药业有限公司 | Fermentation medium and fermentation method of rhG-CSF (recombinant human granulocyte colony-stimulating factor) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004015124A1 (en) * | 2002-07-31 | 2004-02-19 | Lek Pharmaceuticals D.D. | Process for the production of a heterologous protein |
| CN101235362A (en) * | 2007-02-01 | 2008-08-06 | 中国农业科学院哈尔滨兽医研究所 | Composite automatic induction culture medium for expressing exogenous protein by pronucleus expression system |
| CN102154189A (en) * | 2010-12-31 | 2011-08-17 | 山东新时代药业有限公司 | Fermentation culture method of rhG-CSF (recombinant human granulocyte colony-stimulating factor) recombination engineering bacteria |
-
2014
- 2014-08-14 CN CN201410401268.6A patent/CN104152515B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004015124A1 (en) * | 2002-07-31 | 2004-02-19 | Lek Pharmaceuticals D.D. | Process for the production of a heterologous protein |
| CN101235362A (en) * | 2007-02-01 | 2008-08-06 | 中国农业科学院哈尔滨兽医研究所 | Composite automatic induction culture medium for expressing exogenous protein by pronucleus expression system |
| CN102154189A (en) * | 2010-12-31 | 2011-08-17 | 山东新时代药业有限公司 | Fermentation culture method of rhG-CSF (recombinant human granulocyte colony-stimulating factor) recombination engineering bacteria |
Non-Patent Citations (6)
| Title |
|---|
| DEVLIN,J.J.,ET AL.: "Accession No. M17706.1，Human granulocyte colony stimulating factor mRNA, complete cds", 《GENBANK DATABASE》 * |
| H. TIAN,ET AL.: ""Optimization of auto-induction medium for G-CSF production by Escherichia coli using artificial neural networks coupled with genetic algorithm"", 《WORLD J MICROBIOL BIOTECHNOL》 * |
| LIANGHUI JIA,ET AL.: "From shake flasks to bioreactors: survival of E. coli cells harboring pGST–hPTH through auto-induction by controlling initial content of yeast extract", 《APPL MICROBIOL BIOTECHNOL》 * |
| 文莹等: "《现代微生物研究技术》", 31 October 2008, 中国农业大学出版社 * |
| 郑剑等: "乳糖诱导高分子量重组蛛丝蛋白发酵培养基优化", 《中国生物工程杂志》 * |
| 顾娟等: "人胰高血糖素样肽-1突变体融合蛋白在大肠杆菌中的自诱导表达优化", 《微生物学通报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105002103A (en) * | 2015-06-06 | 2015-10-28 | 山东新时代药业有限公司 | Fermentation method for recombinant G-CSF(15-75) polypeptide pichia pastoris |
| CN105002103B (en) * | 2015-06-06 | 2018-08-14 | 山东新时代药业有限公司 | A kind of recombination G-CSF（15-75）The fermentation process of polypeptide Pichia yeast |
| CN106995793A (en) * | 2017-01-18 | 2017-08-01 | 天津市中升挑战生物科技有限公司 | A kind of fermentation process in high density for recombinating bG-CSF engineering bacteria |
| CN110066331A (en) * | 2018-01-23 | 2019-07-30 | 江苏恒瑞医药股份有限公司 | A kind of preparation method of recombinant human granulocyte colony stimulating factor |
| CN114350588A (en) * | 2021-12-31 | 2022-04-15 | 山东新时代药业有限公司 | Fermentation medium and fermentation method of rhG-CSF (recombinant human granulocyte colony-stimulating factor) |
| CN114350588B (en) * | 2021-12-31 | 2024-03-15 | 山东新时代药业有限公司 | Fermentation medium of rhG-CSF and fermentation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104152515B (en) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102132132B1 (en) | Fermentation method to improve recombinant human collagen production level | |
| CN102154189B (en) | A kind of fermentation culture method of rhG-CSF recombinant bacterial strain | |
| CN106566795A (en) | Culture medium and culture method for efficiently expressing plasmid DNA through Escherichia coli engineering bacteria | |
| CN104152515A (en) | Medium used for preparation of recombinant human granulocyte colony stimulating factor and fermentation method | |
| CN102617724B (en) | A kind of porcine defensin pBD1 polypeptide and applying in suppression pig pathogenic bacteria | |
| CN101139390A (en) | Pig gamma interferon and encoding genes and use thereof | |
| CN111733200A (en) | Fermentation process for improving production level of recombinant collagen by adjusting addition mode of PTM1 | |
| CN105543144A (en) | Culture medium of Escherichia coli suitable for expressing crybb2 antigen protein, and fermentation method and application thereof | |
| CN101665798B (en) | Method for preparing recombinant human serum albumin and interferon alpha fusion protein | |
| CN105002103A (en) | Fermentation method for recombinant G-CSF(15-75) polypeptide pichia pastoris | |
| CN103012577B (en) | Recombinant porcine interleukin 4, and encoding gene and expression method thereof | |
| CN107794274A (en) | A kind of people source antalzyme protein production technology | |
| CN102180959B (en) | Improved chook Interleukin-2 protein and preparation method thereof | |
| CN103012578B (en) | Recombinant porcine interleukin 2, and encoding gene and expression method thereof | |
| CN102936602A (en) | Recombinant human insulin-like growth factor-2 protein and production method thereof | |
| EA015498B1 (en) | Process for preparing human g-csf | |
| CN103589769A (en) | High density fermentation method of recombinant porcine interferon alpha 1 (rPoIFN alpha 1) gene engineering bacteria | |
| CN107988294A (en) | Adjust the zymotechnique that temperature improves recombination human source collagen production level | |
| CN107099569B (en) | Method for large-scale fermentation production of recombinant human interferon beta 1b protein | |
| CN107988293B (en) | Fermentation process for improving production level of recombinant human-derived collagen by adjusting pressure | |
| CN105950538B (en) | A method of promoting Miyarisan Fermentative growth | |
| CN110527690A (en) | A kind of heat resistant type tannase and its application | |
| CN110607306A (en) | Expression method of recombinant porcine epidermal growth factor | |
| CN106749609B (en) | Chicken alpha interferon and preparation method thereof | |
| CN101412991B (en) | Method for preparing mannanase by using glycerol as carbon source and fedbatch of substrate for induction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 211112 Kejian Road 699, Jiangning District, Nanjing City, Jiangsu Province Applicant after: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. Address before: 211112 Kejian Road 699, Jiangning District, Nanjing City, Jiangsu Province Applicant before: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230531 Address after: 211112 No. 766, Koning Road, gaoxinyuan, Jiangning District, Nanjing City, Jiangsu Province Patentee after: Jiangsu aosaikang biomedical Co.,Ltd. Address before: 211112 Kejian Road 699, Jiangning District, Nanjing City, Jiangsu Province Patentee before: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |